Fayakun Healthcare

In India, the pharmaceutical industry plays a crucial role in both domestic and global markets. Ensuring the quality, safety, and efficacy of pharmaceutical products is essential for success. This is where adherence to cGXP becomes vital. GXP, or Good Practice, refers to a set of guidelines and regulations that ensure the quality, safety, and efficacy of pharmaceutical products and medical devices throughout their lifecycle. It encompasses several critical areas, including Good Manufacturing Practices (GMP), Good Clinical Practices (GCP), Good Laboratory Practices (GLP), and Good Distribution Practices (GDP), each focusing on different aspects of the production, testing, and distribution process. Recently, several alarming incidents have underscored the critical importance of stringent cGXP adherence. Reports from across the globe have highlighted cases where substandard pharmaceutical products caused severe harm, including fatalities. For instance, in October 2022, contaminated cough ...

  India’s pharmaceutical industry, recognized as the "pharmacy of the world," finds itself at a critical point in its evolution, adapting to rapidly changing regulatory landscapes. With an increasing emphasis on quality, safety, and efficacy, the future of regulatory compliance in India presents both transformative opportunities and challenges. Companies of all sizes will need to innovate and implement robust practices to remain competitive amid heightened scrutiny and alignment with global standards. A key shift in this landscape is the comprehensive integration of guidelines outlined in Schedule M. In the coming years, all pharmaceutical companies, regardless of size, will need to rigorously apply these guidelines. The alignment of Schedule M with WHO’s Technical Report Series (TRS) and ISO standards underscores its growing significance. As of January 2024, only about 2,000 out of approximately 10,500 drug manufacturing units in India meet WHO’s GMP guidelines, indicating t...